Specialty Generics Market Size, Share & Trends Analysis Report By Type (Injectables, Oral Drugs), By Application (Oncology, Inflammatory Conditions, Hepatitis C), By End-use (Specialty, Retail)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030
Chapter 1 Methodology and Scope
1.1 Market Segmentation
1.1.1 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Nova one advisor’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Primary Sources
1.11 List of Abbreviations
1.12 Objectives
1.12.1 Objective 1
1.12.2 Objective 2
1.12.3 Objective 3
1.12.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Market Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Regulatory and Reimbursement Framework
3.4 Market Variable Analysis
3.4.1 Market driver analysis
3.4.1.1 Rising number of off-patent specialty drugs
3.4.1.2 Escalating demand for low-cost generic specialty drugs
3.4.1.3 Increasing prevalence of chronic disease
3.4.1.4 Increasing emphasis to cut down healthcare expenditure
3.4.2 Market restraint analysis
3.4.2.1 High costs associated with specialty generics
3.4.2.2 Delay in new drug launches
3.5 Industry Analysis Tools
3.5.1 Porter's five forces analysis
3.5.2 PESTEL Analysis
3.6 Pipeline Analysis
Chapter 4 Specialty Generics Market - Segment Analysis, by Type, 2017 - 2030
4.1 Specialty Generics Market: Type Movement Analysis
4.2 Injectables
4.2.1 Injectables market, 2017 - 2030
4.3 Oral Drugs
4.3.1 Oral drugs market, 2017 - 2030
4.4 Others
4.4.1 Others market, 2017 - 2030
Chapter 5 Specialty generics Market - Segment Analysis, by Application, 2017 - 2030
5.1 Specialty Generics Market: Application Movement Analysis
5.2 Oncology
5.2.1 Oncology market, 2017 - 2030
5.3 Inflammatory Conditions
5.3.1 Inflammatory conditions market, 2017 - 2030
5.4 Multiple Sclerosis
5.4.1 Multiple sclerosis market, 2017 - 2030
5.5 Hepatitis C
5.5.1 Hepatitis C market, 2017 - 2030
5.6 Others
5.6.1 Others market, 2017 - 2030
Chapter 6 Specialty generics Market - Segment Analysis, by End-Use, 2017 - 2030
6.1 Specialty Generics Market: End-Use Movement Analysis
6.2 Specialty Pharmacy
6.2.1 Specialty pharmacy market, 2017 - 2030
6.3 Retail Pharmacy
6.3.1 Retail pharmacy market, 2017 - 2030
6.4 Hospital Pharmacy
6.4.1 Hospital pharmacy market, 2017 - 2030
Chapter 7 Specialty generics Market - Segment Analysis, By Region, 2017 - 2030
7.1 Specialty Generics Market, Market Share by Region, 2021 & 2030
7.1.1 North America
7.1.1.1 North America market estimates and forecast, 2017 - 2030
7.1.1.2 U.S.
7.1.1.2.1 U.S. market estimates and forecast, 2017 - 2030
7.1.1.3 Canada
7.1.1.3.1 Canada market estimates and forecast, 2017 - 2030
7.1.2 Europe
7.1.2.1 Europe market estimates and forecast, 2017 - 2030
7.1.2.2 U.K.
7.1.2.2.1 U.K. market estimates and forecast, 2017 - 2030
7.1.2.3 Germany
7.1.2.3.1 Germany market estimates and forecast, 2017 - 2030
7.1.2.4 France
7.1.2.4.1 France market estimates and forecast, 2017 - 2030
7.1.2.5 Spain
7.1.2.5.1 Spain market estimates and forecast, 2017 - 2030
7.1.2.6 Italy
7.1.2.6.1 Italy market estimates and forecast, 2017 - 2030
7.1.3 Asia Pacific
7.1.3.1 Asia Pacific market estimates and forecast, 2017 - 2030
7.1.3.2 Japan
7.1.3.2.1 Japan market estimates and forecast, 2017 - 2030
7.1.3.3 China
7.1.3.3.1 China market estimates and forecast, 2017 - 2030
7.1.3.4 India
7.1.3.4.1 India market estimates and forecast, 2017 - 2030
7.1.3.5 Australia
7.1.3.5.1 Australia market estimates and forecast, 2017 - 2030
7.1.3.6 South Korea
7.1.3.6.1 South Korea market estimates and forecast, 2017 - 2030
7.1.4 Latin America
7.1.4.1 Latin America market estimates and forecast, 2017 - 2030
7.1.4.2 Brazil
7.1.4.2.1 Brazil market estimates and forecast, 2017 - 2030
7.1.4.3 Mexico
7.1.4.3.1 Mexico market estimates and forecast, 2017 - 2030
7.1.4.4 Argentina
7.1.4.4.1 Argentina market estimates and forecast, 2017 - 2030
7.1.5 Middle East and Africa
7.1.6 Middle East and Africa market estimates and forecast, 2017 - 2030
7.1.6.1 South Africa
7.1.6.1.1 South Africa market estimates and forecast, 2017 - 2030
7.1.6.2 Saudi Arabia
7.1.6.2.1 Saudi Arabia market estimates and forecast, 2017 - 2030
7.1.6.3 UAE
7.1.6.3.1 UAE market estimates and forecast, 2017 - 2030
Chapter 8 Specialty Generics Market-Competitive Analysis
8.1 Major Deals and Strategic Alliances Analysis
8.1.1 New Product Launch
8.1.2 Mergers and Acquisitions
8.1.3 Partnerships and Strategic Collaborations
8.1.4 Conferences and Campaigns
8.2 Company Categorization
8.2.1 Market Differentiators
8.2.2 Innovators
8.2.3 Market Leaders
8.3 Vendor Landscape
8.3.1 List of key distributors and channel partners
8.3.2 Key customers
8.4 Heat map analysis
8.5 Public Companies
8.5.1 Key company market share analysis, 2021
8.5.2 Company Market Position Analysis
8.6 Private Companies
8.6.1 List of key emerging companies
8.6.2 Regional Network Map
8.7 Company Profiles
8.7.1 Teva Pharmaceutical Industries Ltd
8.7.1.1 Company overview
8.7.1.2 Financial performance
8.7.1.3 Product benchmarking
8.7.1.4 Strategic initiatives
8.7.2 Viatris Inc.
8.7.2.1 Company overview
8.7.2.2 Financial performance
8.7.2.3 Product benchmarking
8.7.2.4 Strategic initiatives
8.7.3 Novartis AG (Sandoz International GmbH)
8.7.3.1 Company overview
8.7.3.2 Financial performance
8.7.3.3 Product benchmarking
8.7.3.4 Strategic initiatives
8.7.4 Fresenius Kabi Brasil Ltda
8.7.4.1 Company overview
8.7.4.2 Financial performance
8.7.4.3 Product benchmarking
8.7.4.4 Strategic initiatives
8.7.5 Mallinckrodt
8.7.5.1 Company overview
8.7.5.2 Financial performance
8.7.5.3 Product benchmarking
8.7.5.4 Strategic initiatives
8.7.6 Bausch Health Companies Inc. (Valeant Pharmaceuticals International, Inc.)
8.7.6.1 Company overview
8.7.6.2 Financial performance
8.7.6.3 Product benchmarking
8.7.6.4 Strategic initiatives
8.7.7 STADA Arzneimittel AG
8.7.7.1 Company overview
8.7.7.2 Financial performance
8.7.7.3 Product benchmarking
8.7.8 Endo Pharmaceuticals Inc.
8.7.8.1 Company overview
8.7.8.2 Financial performance
8.7.8.3 Product benchmarking
8.7.8.4 Strategic initiatives
8.7.9 Apotex Corp.
8.7.9.1 Company overview
8.7.9.2 Product benchmarking
8.7.9.3 Strategic initiatives
8.7.10 Sun Pharmaceutical Industries Ltd.
8.7.10.1 Company overview
8.7.10.2 Financial performance
8.7.10.3 Product benchmarking
8.7.10.4 Strategic initiatives
8.7.11 Dr. Reddy's Laboratories Ltd
8.7.11.1 Company overview
8.7.11.2 Financial performance
8.7.11.3 Product benchmarking
8.7.11.4 Strategic initiatives
8.7.12 Hikma Pharmaceuticals PLC
8.7.12.1 Company overview
8.7.12.2 Financial performance
8.7.12.3 Product benchmarking
8.7.12.4 Strategic initiatives